201 related articles for article (PubMed ID: 21705501)
1. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Walz C; Erben P; Ritter M; Bloor A; Metzgeroth G; Telford N; Haferlach C; Haferlach T; Gesk S; Score J; Hofmann WK; Hochhaus A; Cross NC; Reiter A
Blood; 2011 Aug; 118(8):2239-42. PubMed ID: 21705501
[TBL] [Abstract][Full Text] [Related]
2. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
4. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
[TBL] [Abstract][Full Text] [Related]
5. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
von Bubnoff N; Rummelt C; Menzel H; Sigl M; Peschel C; Duyster J
Leukemia; 2010 Aug; 24(8):1523-5. PubMed ID: 20520641
[No Abstract] [Full Text] [Related]
6. Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.
Munthe-Kaas MC; Forthun RB; Brendehaug A; Eek AK; Høysæter T; Osnes LTN; Prescott T; Spetalen S; Hovland R
J Pediatr Hematol Oncol; 2021 May; 43(4):e508-e511. PubMed ID: 32852395
[TBL] [Abstract][Full Text] [Related]
7. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.
Falchi L; Mehrotra M; Newberry KJ; Lyle LM; Lu G; Patel KP; Luthra R; Popat U; Verstovsek S
Leukemia; 2014 Oct; 28(10):2090-2. PubMed ID: 24854988
[No Abstract] [Full Text] [Related]
8. FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Illmer T; Ehninger G
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S24-34. PubMed ID: 18282363
[TBL] [Abstract][Full Text] [Related]
9. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
[TBL] [Abstract][Full Text] [Related]
10. Two myeloid leukemia cases with rare
Zhang H; Paliga A; Hobbs E; Moore S; Olson S; Long N; Dao KT; Tyner JW
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30559310
[TBL] [Abstract][Full Text] [Related]
11. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
12. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Pratz KW; Sato T; Murphy KM; Stine A; Rajkhowa T; Levis M
Blood; 2010 Feb; 115(7):1425-32. PubMed ID: 20007803
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
14. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
15. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Fesler MJ; Richart JM; Petruska PJ
Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
[No Abstract] [Full Text] [Related]
16. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.
Chung A; Hou Y; Ohgami RS; Von Gehr A; Fisk DG; Roskin KM; Li X; Gojenola L; Bangs CD; Arber DA; Fire AZ; Cherry AM; Zehnder JL; Gotlib J; Merker JD
Cancer Genet; 2017 Oct; 216-217():10-15. PubMed ID: 29025582
[TBL] [Abstract][Full Text] [Related]
17. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
[TBL] [Abstract][Full Text] [Related]
18. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Lierman E; Lahortiga I; Van Miegroet H; Mentens N; Marynen P; Cools J
Haematologica; 2007 Jan; 92(1):27-34. PubMed ID: 17229632
[TBL] [Abstract][Full Text] [Related]
19. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
